https://ironwoodpharma.com/ironwood-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-results-exceeding-or-meeting-full-year-2020-financial-guidance-provides-full-year-2021-financial-guidance/ 2022-12-20T18:19:17-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-upcoming-investor-conferences-2/ 2022-12-20T18:19:16-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-first-quarter-2021-investor-update-call/ 2022-12-20T18:19:16-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-reports-first-quarter-2021-results/ 2022-12-20T18:19:16-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-new-150-million-share-repurchase-program/ 2022-12-20T18:19:16-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-new-linaclotide-data-and-unveil-findings-from-gi-disease-surveys-at-digestive-disease-week-2021/ 2022-12-20T18:19:16-05:00 https://ironwoodpharma.com/more-than-a-third-of-surveyed-ibs-c-patients-reported-that-their-symptoms-worsened-during-covid-19-according-to-new-survey-findings-presented-by-ironwood-pharmaceuticals-at-digestive-disease-week/ 2022-12-20T18:19:16-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-agreement-with-teva-involving-linzess-linaclotide-72-mcg-dosage-strength/ 2022-12-20T18:19:16-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-leadership-updates/ 2022-12-20T18:19:16-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-that-the-american-journal-of-gastroenterology-publishes-full-results-from-positive-linzess-linaclotide-phase-iiib-trial-in-adults-with-irritable-bowel-syndro/ 2022-12-20T18:19:16-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-second-quarter-2021-investor-update-call/ 2022-12-20T18:19:16-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-appoints-john-minardo-as-chief-legal-officer/ 2022-12-20T18:19:16-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-reports-strong-second-quarter-2021-results-raises-full-year-guidance/ 2022-12-20T18:19:16-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-fda-approval-of-revised-linzess-linaclotide-label/ 2022-12-20T18:19:16-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-participate-in-upcoming-september-investor-conferences/ 2022-12-20T18:19:16-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-third-quarter-2021-investor-update-call/ 2022-12-20T18:19:16-05:00 https://ironwoodpharma.com/more-than-90-of-surveyed-ibs-c-patients-who-had-an-er-visit-or-hospitalization-in-the-past-year-identified-abdominal-pain-as-a-symptom-that-led-to-the-visit-according-to-data-announced-by-ironwood-ph/ 2022-12-20T18:19:16-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-expands-pipeline-by-signing-an-option-agreement-to-acquire-an-exclusive-license-with-cour-pharmaceuticals-to-develop-and-commercialize-cnp-104-for-the-treatment-of-primary-bil/ 2022-12-20T18:19:15-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-reports-third-quarter-2021-results-and-provides-corporate-development-update/ 2022-12-20T18:19:15-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference/ 2022-12-20T18:19:15-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-update-on-fy-2021-financial-guidance-and-announces-fy-2022-financial-guidance/ 2022-12-20T18:19:14-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-fourth-quarter-and-full-year-2021-investor-update-call/ 2022-12-20T18:19:14-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-results-linzess-linaclotide-achieves-blockbuster-status-as-u-s-net-sales-exceed-1-billion-in-2021/ 2022-12-20T18:19:14-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-upcoming-investor-conferences/ 2022-12-20T18:19:14-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-first-quarter-2022-investor-update-call/ 2022-12-20T18:19:14-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-reports-first-quarter-2022-results-maintains-full-year-2022-financial-guidance/ 2022-12-20T18:19:14-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-new-iw-3300-and-linaclotide-data-at-digestive-disease-week-2022/ 2022-12-20T18:19:14-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-second-quarter-2022-investor-update-call/ 2022-12-20T18:19:14-05:00